Responsiveness of walking-based outcome measures after multiple sclerosis relapses following steroid pulses

Medical Science Monitor

Volumn 17, Issue 12, 2011, Pages

  Grčić, Petar Filipović ^a   Matijaca, Meri ^a   Lušić, Ivo ^a   Čapkun, Vesna ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Intravenous methylprednisolone; Multiple sclerosis; Relapses; Responsiveness; Walkingbased measures

Indexed keywords

METHYLPREDNISOLONE SODIUM SUCCINATE;

2 MINUTE TIMED WALK; 25 FOOT WALK TEST; ACCELEROMETER; ADULT; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS WALKING SCALE 12; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; SIX SPOT STEP TEST; TREATMENT DURATION; WALKING; WALKING SPEED;

EID: 82755168740     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.882130     Document Type: Article

References (37)

1. Schwid SR, Goodman AD, Apatoff BR et al: Are quantative functional measures more sensitive to worsening MS than are traditional measures? Neurology, 2000; 55: 1901-3
2. Swingler R, Compston DAS: The morbidity of multiple sclerosis. Q J Med, 1992; 83: 325-37
3. Hobart JC, Lamping DL, Fitzpatrick R et al: The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain, 2001; 124: 962-73
4. Heesen C, Bohm J, Reich C et al: Patient perception of bodily function in multiple sclerosis: gait and visual function are the most valuable. Mult Scler, 2008; 14: 988-91
5. Goodman AD, Brown TR, Krupp LB et al: Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet, 2009; 373: 732-38
6. Sanofi-Aventis. Efficacy, safety and tolerability of nerispiridine in patients with multiple sclerosis. Last updated 2010 Mar 22. ClinicalTrials. gov Web site. Available from: http://clinicaltrials.gov/ct2/show/NCT00811902. Accessed Apr 9 2010
7. Kurtzke JF: A new scale for evaluating disability in multiple sclerosis. Neurology, 1955; 5: 580-83
8. Pearson OR, Busse ME, van Deursen RWM, Wiles CM: Quantification of walking mobility in neurological disorders. Q J Med, 2004; 97: 463-75
9. Hobart J, Freeman J, Thompson A: Kurtzke scales revised: the application of psychometric methods to clinical intuition. Brain, 2000; 123: 1027-40
10. McGuigan C, Hutchinson M: Confirming the validity and responsiveness of the Multiple Sclerosis Walking Scale-12 (MSWS-12). Neurology, 2004; 62: 2103-5
11. Hobart JC, Riazi A, Lamping DL et al: How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales. J Neurol Neurosurg Psychiatry, 2005; 76: 1539-43
12. Giordano A, Pucci E, Naldi P et al: Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study. J Neurol Neurosurg Psychiatry, 2009; 80: 1023-28
13. Cohen J: The earth is round (p<.05). Am Psychol, 1994; 49: 997-1003
14. O'Connor RJ, Cano SJ, Thompson AJ, Hobart JC: Exploring rating scale responsiveness: does the total score reflect the sum of its parts? Neurology, 2004; 62: 1842-44
15. Hobart JC, Lamping DL, Freeman JA et al: Evidence-based measurement: which disability scale for neurological rehabilitation? Neurology, 2001; 57: 639-44
16. McDonald WI, Compston A, Edan G et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol, 2001; 50: 121-27
17. Goraj B: Multiple sclerosis diagnostic criteria-an update. Pol Przegl Radiol, 2010; 75(Suppl.1): 110-10
18. Kurtzke JF: Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 1983; 33: 1444-52
19. Lienert C, Lechner-Scott J, Muller U, Kappos L: Reliability of EDSS and FS-score rating can be improved by standardised training. Mult Scler, 2002; 8: S33
20. Hobart JC, Riazi A, Lamping DL et al: Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12). Neurology, 2003; 60: 31-36
21. Cutter GR, Baier ML, Rudick RA et al: Development of a multiple sclerosis functional composite as a clinical trail outcome measure. Brain, 1999; 122: 871-82
22. Nieuwenhius MM, Van Tongren H, Sorensen PS, Ravnborg M: The Six Spot Step Test: a new measurement for walking ability in multiple sclerosis. Mult Scler, 2006; 12: 495-500
23. American Thoracic Socity Statement: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med, 2002; 166: 111-17
24. Kasiz LE, Anderson JJ, Meenan RF: Effect sizes for interpreting changes in health status. Med Care, 1989; 27: 178-89
25. Katz JN, Larson MG, Phillips CB et al: Comparative measurement sensitivity of short and longer health status instruments. Med Care, 1992; 30: 917-25
26. Liang MH: Evaluating instrument responsiveness. J Rheumatol, 1995; 22: 1191-92
27. nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988
28. Liang MH, Larson MG, Cullen KE, Schwartz JA: Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. Arthritis Rheum, 1985; 28: 542-47
29. Durelli L, Cocito D, Riccio A et al: High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunological corelations. Neurology, 1986; 36: 238-43
30. Milligan NM, Newcombe R, Compston DAS: A double-blind controlled trail of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry, 1987; 50: 511-16
31. Weikert M, Motl RW, Suh Y et al: Accelerometry in persons with multiple sclerosis: measurement of physical activity or walking mobility? J Neurol Sci, 2010; 290: 6-11
32. Motl RW, Snook EM, Agiovlastis S: Does an accelerometer accurately measure steps taken under controlled conditions in adults with mild multiple sclerosis? Disabil Health J, 2011; 4: 52-57
33. Motl RW, Snook EM, McAuley E et al: Demographic correlates of physical activity in individuals with multiple sclerosis. Disabil Rehabil, 2007; 29: 1301-4
34. Doerksen SE, Motl RW, McAuley E: Environmental correlates of physical activity in multiple sclerosis: a cross-sectional study. Int J Behav Nutr Phys Act, 2007; 4: 49
35. Motl RW, Goldman MD, Benedict RH: Walking impairment in patients with multiple sclerosis: exercise training as a treatment option. Neuropsychiatr Dis Treat, 2010; 16: 767-74
36. Nikfar S, Rahimi R, Rezaie A, Abdollahi M: A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis. Arch Med Sci, 2010; 2: 236-44
37. Muss C, Stejskal V, Titel E: The effectiveness of choline citrate infusions monitored by lymphocyte transformation test (LTT) in multiple sclerosis. A new approach to the diagnosis and treatment of the disease. Neuro Endocrinol Lett, 2009; 30: 331-34